Tags

Type your tag names separated by a space and hit enter

[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2].
Hamostaseologie. 2005 08; 25(3):301-10.H

Abstract

Proteolytic factors belonging t the plasminogen activator family (plasmin, u-PA, t-PA, u-PAR, PAI-1, and PAI-2), which usually are involved in blood clotting and degradation of blood clots, are also present in healthy and diseased tissue of the kidney, lung, liver, gastro-intestinal tract, breast, prostate, ovary, and brain. These factors are engaged in brain development, angiogenesis and vascular invasion, wound healing as well as in placenta development and embryogenesis. Plasminogen activators u-PA and t-PA, their inhibitors PAI-1 and PAI-2, and the u-PA-receptor (u-PAR, CD87) are often elevated in solid malignant tumour tissues compared to their normal counterparts. In breast cancer patients, an elevated tumour tissue extract antigen content of u-PA, PAI-1, and u-PAR is associated with increased tumour aggressiveness and poor prognosis; in contrary, an elevated content of t-PA and PAI-2 indicates a favourable prognosis. For clinical relevant determination of these proteolytic factors in tumour tissue extracts, only enzymo-immunometric tests (ELISA) are recommended. Enzymometric and enzymographic tests are actually conducted only in an experimental, preclinical context.

Authors+Show Affiliations

Klinische Forschergruppe, Frauenklinik der Technischen Universität München, Ismaninger Str. 22, 81675 München.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

ger

PubMed ID

16113755

Citation

Mengele, K, et al. "[Tumor-associated Prognostic Factors of the Plasminogen Activator Family: Determination and Clinical Value of u-PA, t-PA, PAI-1, and PAI-2]." Hamostaseologie, vol. 25, no. 3, 2005, pp. 301-10.
Mengele K, Harbeck N, Reuning U, et al. [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]. Hamostaseologie. 2005;25(3):301-10.
Mengele, K., Harbeck, N., Reuning, U., Magdolen, V., & Schmitt, M. (2005). [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]. Hamostaseologie, 25(3), 301-10.
Mengele K, et al. [Tumor-associated Prognostic Factors of the Plasminogen Activator Family: Determination and Clinical Value of u-PA, t-PA, PAI-1, and PAI-2]. Hamostaseologie. 2005;25(3):301-10. PubMed PMID: 16113755.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]. AU - Mengele,K, AU - Harbeck,N, AU - Reuning,U, AU - Magdolen,V, AU - Schmitt,M, PY - 2005/8/23/pubmed PY - 2005/10/5/medline PY - 2005/8/23/entrez SP - 301 EP - 10 JF - Hamostaseologie JO - Hamostaseologie VL - 25 IS - 3 N2 - Proteolytic factors belonging t the plasminogen activator family (plasmin, u-PA, t-PA, u-PAR, PAI-1, and PAI-2), which usually are involved in blood clotting and degradation of blood clots, are also present in healthy and diseased tissue of the kidney, lung, liver, gastro-intestinal tract, breast, prostate, ovary, and brain. These factors are engaged in brain development, angiogenesis and vascular invasion, wound healing as well as in placenta development and embryogenesis. Plasminogen activators u-PA and t-PA, their inhibitors PAI-1 and PAI-2, and the u-PA-receptor (u-PAR, CD87) are often elevated in solid malignant tumour tissues compared to their normal counterparts. In breast cancer patients, an elevated tumour tissue extract antigen content of u-PA, PAI-1, and u-PAR is associated with increased tumour aggressiveness and poor prognosis; in contrary, an elevated content of t-PA and PAI-2 indicates a favourable prognosis. For clinical relevant determination of these proteolytic factors in tumour tissue extracts, only enzymo-immunometric tests (ELISA) are recommended. Enzymometric and enzymographic tests are actually conducted only in an experimental, preclinical context. SN - 0720-9355 UR - https://www.unboundmedicine.com/medline/citation/16113755/[Tumor_associated_prognostic_factors_of_the_plasminogen_activator_family:_determination_and_clinical_value_of_u_PA_t_PA_PAI_1_and_PAI_2]_ DB - PRIME DP - Unbound Medicine ER -